Nyxoah SA (NYXH) Form 424B5 — Jun 4, 2026
Nyxoah SA filed a preliminary prospectus supplement for an undetermined number of ordinary shares, marking a shelf takedown from its $200 million F-3 registration. The offering aims to raise capital for U.S. commercialization of its Genio sleep apnea device, R&D, and general corporate purposes, with net proceeds to be determined at pricing. The filing reveals Nyxoah has a negative net tangible book value of €(0.31) per share and an accumulated deficit of €321.7 million, signaling significant dilution for new investors.
Key figures
- Total Debt
- 61727000
- Cash Position
- 25900000
- Shares Outstanding
- 43662403
- Shelf Capacity USD
- 200000000
- Atm Program Sold USD
- 32800000
- Eib Loan Tranche2 EUR
- 13800000
- Convertible Notes EUR
- 22500000
- Warrants Outstanding
- 3367569
- Last Reported Price EUR
- 2.45
- Last Reported Price USD
- 2.85
- Warrants Not Yet Granted
- 462677
- Total Equity Financing Raised EUR
- 332500000
Price after filing
Close on the filing date to close N calendar days later (from $2.88). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.